Asieris Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 162 million yuan
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Asieris disclosed its semi-annual report for 2025, stating that the company achieved revenue of 130 million yuan during the reporting period, a year-on-year increase of 61.80%; the net profit attributable to the parent company was a loss of 162 million yuan; the net profit excluding non-recurring gains and losses was a loss of 177 million yuan; basic earnings per share were -0.29 yuan
According to the Zhitong Finance APP, Asieris (688176.SH) disclosed its semi-annual report for 2025, reporting revenue of 130 million yuan, a year-on-year increase of 61.80%; a net loss attributable to shareholders of 162 million yuan; a net loss of 177 million yuan after deducting non-recurring items; and a basic earnings per share of -0.29 yuan